{"id":162821,"date":"2026-11-19T09:13:11","date_gmt":"2026-11-19T09:13:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/162821\/"},"modified":"2026-11-19T09:13:11","modified_gmt":"2026-11-19T09:13:11","slug":"novartis-remains-on-a-growth-trajectory-despite-expiring-patents","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/162821\/","title":{"rendered":"Novartis Remains on a Growth Trajectory Despite Expiring Patents"},"content":{"rendered":"<p>Pharmaceuticals<\/p>\n<p><img alt=\"Novartis Remains on a Growth Trajectory Despite Expiring Patents (File photo)\" fetchpriority=\"high\" loading=\"eager\" width=\"1280\" height=\"720\" decoding=\"async\" data-nimg=\"1\" class=\"object-cover\" style=\"color:transparent\"   src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/11\/6a0805e6-13d3-4d4f-9423-568fefe49449.jpg\"\/><\/p>\n<p class=\"text-dark-gray text-small mt-2\">Novartis Remains on a Growth Trajectory Despite Expiring Patents (File photo)<\/p>\n<p class=\"text-gray text-smaller mt-1 [.ticker-entry_&amp;]:border-b [.ticker-entry_&amp;]:border-aluminum [.ticker-entry_&amp;]:pb-1\">Keystone<\/p>\n<p class=\"c-stacked-spacing a-paragraph a-paragraph--lead text-h4 leading-26 md:leading-28 text-navy p-4 pb-8 md:px-0 md:pt-8\" data-t-name=\"Paragraph\">At its Investor Day, Novartis expressed confidence in its growth prospects. The company is relying on its pipeline, which includes numerous product candidates, to help it navigate the upcoming patent cliff.<\/p>\n<p><img alt=\"Keystone-SDA\" loading=\"lazy\" width=\"40\" height=\"40\" decoding=\"async\" data-nimg=\"1\" class=\"h-full w-full rounded-full object-cover\" style=\"color:transparent\"  src=\"https:\/\/bluewin-prod-sc-images.imgix.net\/2026\/04\/07\/8f8bf2bc-2db8-4d30-a567-72697f869653.heif?w=96&amp;auto=format&amp;s=07db0ac73ee5d1f68cd7a05910f2bdf5\"\/><\/p>\n<p class=\"author-names text-navy text-small\">Keystone-SDA<\/p>\n<p><img alt=\"\" aria-hidden=\"true\" loading=\"lazy\" width=\"12\" height=\"12\" decoding=\"async\" data-nimg=\"1\" class=\"mr-1 h-3 w-3\" style=\"color:transparent\"  src=\"https:\/\/www.bluewin.ch\/_next\/static\/media\/021-clock.24ldz2iukf4_m.svg?w=32\"\/>Today at 08:20<\/p>\n<p class=\"c-paragraph text-standard wrap-break-word text-dark-gray font-thesans w-full\">For the period from 2026 to 2031, the pharmaceutical company is aiming for average annual revenue growth of 5 percent, according to a press release issued Thursday. In addition, the core profit margin is expected to rise back above 40 percent by 2029.<\/p>\n<p class=\"c-paragraph text-standard wrap-break-word text-dark-gray font-thesans w-full\">At the same time, the company raised its peak sales forecasts for three key drugs. For the multiple sclerosis drug Kesimpta, Novartis now expects peak annual sales of $8 billion, up from the previous forecast of $6 billion. The forecasts for Scemblix\u2014a drug used to treat certain forms of chronic myeloid leukemia\u2014and the cholesterol-lowering drug Leqvio were each raised to $5 billion from $4 billion.<\/p>\n<p class=\"c-paragraph text-standard wrap-break-word text-dark-gray font-thesans w-full\">The company had recently raised its top-line targets for Rhapsido (remibrutinib) to $8 billion. The active ingredient is being developed, among other things, to treat chronic spontaneous and inducible urticaria as well as relapsing-remitting multiple sclerosis. Novartis sees additional billion-dollar potential for other indications of the drug.<\/p>\n<p class=\"c-paragraph text-standard wrap-break-word text-dark-gray font-thesans w-full\">According to the company, this means the group now has nine drugs already on the market, each with peak sales potential ranging from $3 billion to $10 billion. In addition to the drugs mentioned above, this includes Kisqali for breast cancer, Cosentyx for inflammatory diseases, Pluvicto for prostate cancer, the gene therapy portfolio centered on Zolgensma and Itvisma, and Fabhalta for certain rare diseases.<\/p>\n<p>Broad Pipeline Aims to Ensure Growth<\/p>\n<p class=\"c-paragraph text-standard wrap-break-word text-dark-gray font-thesans w-full\">In addition to its existing portfolio, Novartis is focusing on its development pipeline. By 2031, the company expects more than 35 study results that could potentially form the basis for regulatory filings.<\/p>\n<p class=\"c-paragraph text-standard wrap-break-word text-dark-gray font-thesans w-full\">The pipeline includes more than 30 potential high-revenue drug candidates. More than 20 of these are in Phase II or III or in the regulatory approval process. Ten of the late-stage projects have a peak revenue potential of several billion dollars.<\/p>\n<p class=\"c-paragraph text-standard wrap-break-word text-dark-gray font-thesans w-full\">&#8220;We expect to continue growing in 2026, despite the greatest challenge in our company&#8217;s history resulting from the loss of patent protection and market exclusivity,&#8221; Novartis CEO Vas Narasimhan is quoted as saying in the press release.<\/p>\n<p class=\"c-paragraph text-standard wrap-break-word text-dark-gray font-thesans w-full\">As a reminder: At Novartis, patents on key revenue drivers\u2014such as the heart medication Entresto\u2014are expiring, which is weighing on sales.<\/p>\n","protected":false},"excerpt":{"rendered":"Pharmaceuticals Novartis Remains on a Growth Trajectory Despite Expiring Patents (File photo) Keystone At its Investor Day, Novartis&hellip;\n","protected":false},"author":2,"featured_media":162822,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[206,2536],"class_list":["post-162821","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-novartis","tag-pharma"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117642343584861504","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/162821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=162821"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/162821\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/162822"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=162821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=162821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=162821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}